Phaseline

Targets › HA2

HA2 (Unconventional myosin-Ig [Cleaved into: Minor histocompatibility antigen HA-2): drug programs, companies and trials

1 program from 1 company in 2 trials: 1 Phase 3, 1 Phase 1; Oncology; next expected readout Jun 2028.

Unconventional myosin required during immune response for detection of rare antigen-presenting cells by regulating T-cell migration. Unconventional myosins are actin-based motor molecules with ATPase activity and serve in intracellular movements. (UniProt, B0I1T2)

Open in Phaseline: the race on HA2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
TScan TherapeuticsTSC-101
T-cell receptor engineered donor T cells targeting HA-2
HA2Phase 3AMLJun 2028

Conditions

AML (2)

Modalities

small molecule (1)

Companies

TScan Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.